Full-Time

Senior Director Global Regulatory Lead

Regulatory Strategy

Posted on 9/9/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$242k - $313k/yr

+ Annual bonus + Long-term incentive award

Boston, MA, USA

Hybrid

Hybrid schedule requires at least two days on-site per week; remote employees must make periodic office visits.

Master's, PhD

Category
Biology & Biotech (1)

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • An advanced degree (PhD, PharmD, or master's level) in a relevant life sciences discipline is required.
  • At least 12 years of regulatory affairs experience in the pharmaceutical or biotechnology industry is preferred, including 5–7 years of direct responsibility for global regulatory strategy leadership on clinical development programs.
  • Deep expertise in global regulatory strategy development for biologics and/or small-molecule therapeutics, with experience developing regulatory plans across the FDA, EMA, and additional global jurisdictions from pre-IND through post-approval, is required.
  • Extensive experience preparing and leading Health Authority interactions, including FDA pre-IND, Type B, and Type C meetings and EMA Scientific Advice meetings, is required.
  • Thorough knowledge of FDA regulations, including 21 CFR Parts 312 and 314/601, EMA regulatory frameworks, ICH E8(R1), ICH E9(R1), and applicable guidance documents relevant to early clinical development in immunology and inflammation or autoimmune disease indications is required.
  • Ability to operate independently, drive execution of regulatory plans, exercise sound judgment in stakeholder engagement, keep leadership informed, and involve senior management at key decision points is required.
  • Ability to manage multiple concurrent priorities, competing timelines, and development milestones in a matrix biotechnology organization is required.
  • Exceptional written and verbal communication skills, including the ability to translate complex regulatory, scientific, and operational content for executive leadership, Health Authorities, and cross-functional partners, are required.
  • Ability to communicate operational information into clear, actionable insights and provide decisive direction to teams is required.
  • Skill in preparing and delivering presentations, briefing documents, and strategic updates to cross-functional leadership teams, board-level stakeholders, and external regulatory agencies is required.
  • Ability to facilitate productive dialogue in high-stakes meetings, Health Authority interactions, and multi-party collaborations while balancing clarity, diplomacy, and scientific precision is required.
  • Strong active listening skills and the ability to synthesize input from diverse perspectives into clear, actionable communications are required.
Responsibilities
  • Develop and lead integrated global regulatory strategies for assigned pipeline programs in the immunology and inflammation portfolio, including pre-IND planning, IND/CTA submission strategy, Phase I/II/III development planning, and regulatory pathway optimization across major global jurisdictions.
  • Serve as the primary regulatory strategist for assigned program teams by guiding development-plan design, regulatory-risk identification, filing sequencing, and Health Authority engagement strategy.
  • Lead the preparation and execution of regulatory meetings, including timeline management, briefing-document development, strategic meeting preparation, agency interaction management, and translation of Health Authority feedback into actionable development recommendations.
  • Develop and maintain integrated regulatory development plans and regulatory timelines for assigned programs, aligning them with clinical, CMC, and non-clinical development activities and program milestones.
  • Lead IND, CTA, NDA, and BLA submissions, as well as regulatory planning and submission of pediatric development plans.
  • Provide strategic input to clinical protocols, non-clinical study designs, and early CMC development activities to support regulatory acceptability and global development strategy.
  • Monitor and interpret evolving FDA and global regulatory guidance, precedent regulatory decisions, and competitive landscape intelligence, and integrate relevant insights into pipeline regulatory strategy.
  • Evaluate and leverage expedited regulatory pathway opportunities, including Breakthrough Therapy Designation, Fast Track Designation, PRIME designation, and Orphan Drug Designation.
  • Partner with Regulatory Affairs CMC, Clinical Development, Non-Clinical Sciences, Bioanalytics, and Translational Sciences teams to align cross-functional development activities with regulatory strategy.
  • Contribute to regulatory due diligence for pipeline asset evaluations, in-licensing candidates, and business development targets by assessing regulatory risk profiles, development pathway viability, and filing readiness.
  • Maintain appropriate trackers of regulatory activities.
  • Lead cross-functional teams and define and lead regulatory interactions.
  • Assess resource needs for assigned programs and participate with the manager in developing program budgets.
  • Perform other assigned duties and responsibilities.
Desired Qualifications
  • Prior experience in immunology, inflammation, autoimmune disease, or a related therapeutic area is strongly preferred.
  • Knowledge of the lupus regulatory landscape and precedent regulatory decisions is an advantage.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...